Predictors of ventricular tachyarrhythmia in patients with implantable cardioverter-defibrillator and non-ischemic systolic heart failure

• Published in: Kardiologia polska Vol. 81; no. 10; pp. 998 - 1005
• Main Authors: Jędrzejczyk-Patej, Ewa, Mazurek, Michał, Lazar, Monika, Pruszkowska-Skrzep, Patrycja, Sokal, Adam, Kowalczyk, Jacek, Kowalski, Oskar, Kalarus, Zbigniew, Lenarczyk, Radosław
• Format: Journal Article
• Language: English
• Published: Poland 01.01.2023
• Subjects: Atrial Fibrillation - complications; Atrial Fibrillation - therapy; Defibrillators, Implantable - adverse effects; Follow-Up Studies; Heart Failure; Heart Failure, Systolic - complications; Heart Failure, Systolic - therapy; Humans; Risk Factors; Stroke Volume; Tachycardia, Ventricular - etiology; Tachycardia, Ventricular - therapy; Ventricular Fibrillation - etiology; Ventricular Fibrillation - therapy; Ventricular Function, Left; predictors; ventricular arrhythmia; heart failure; appropriate therapy; implantable cardioverter-defibrillator
• ISSN: 0022-9032; 1897-4279
• DOI: 10.33963/v.kp.97000

The benefit derived from implantable cardioverter-defibrillators (ICD) in subjects with non-ischemic systolic HF (NICM) is less well-established. The study aimed to determine the incidence, predictors, and prognostic impact of ventricular arrhythmias in patients with ICD and NICM. The study sample included 377 consecutive patients with ICD or cardiac resynchronization cardioverter-defibrillators (CRT-D, 74% of patients) and NICM implanted and monitored remotely in a university hospital. During the median (interquartile range [IQR]) follow-up of 1645 (960-2675) days, sustained ventricular arrhythmia occurred in 92 patients (24.4%). Of those, ventricular fibrillation (VF), ventricular tachycardia (VT), and both VT and VF occurred in 10 (10.9%), 72 (78.3%), and 10 (10.9%) patients, respectively. Patients with vs. those without ventricular arrhythmia differed concerning sex, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), post-inflammatory etiology, atrial fibrillation/flutter occurrence, and supraventricular arrhythmia (SVT) other than AF/AFL during follow-up. In multivariable Cox regression, LVEDD (hazard ratio [HR], 1.05; 95% confidence interval [CI], 1.003-1.09; P = 0.03), AF/AFL (HR, 1.86; 95% CI, 1.21-2.85; P = 0.004), and SVT (HR, 1.77; 95% CI, 1.10-2.87; P = 0.02) were independent predictors of sustained VT, while AF/AFL (HR, 1.65; 95% CI, 1.07-2.56; P = 0.02) was independent predictor of VF. All-cause mortality in patients with VT/VF was significantly higher than in subjects without sustained ventricular arrhythmias (35.9% vs. 22.4%; P = 0.01). Ventricular arrhythmia occurred in every fourth patient with NICM and ICD during 4.5 years of observation and was associated with significantly worse prognosis than in subjects free of VT/VF. Higher LVEDD, atrial fibrillation/atrial flutter, and supraventricular tachycardia flag patients at risk of ventricular arrhythmia.